Prosecution Insights
Prosecution Insights
6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (17%) |
| §103 only | 2 (33%) |
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MONTANARI, DAVID A | 1 | 64.7% | +49.1% |
| KWON, JOHN SEUNGJAI | 1 | 45.1% | +20.2% |
| MEYERING, SHABANA SHABBEER | 1 | 69.2% | +41.6% |
| SHUPE, ELIZABETH A | 1 | 65.7% | +46.8% |
| GOLDBERG, JEANINE ANNE | 1 | 45.9% | +40.9% |
| WOOLWINE, SAMUEL C | 1 | 60.9% | +20.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16630547 | DNA TARGETS AS TISSUE-SPECIFIC METHYLATION MARKERS | WOOLWINE, SAMUEL C | 29d |
| 18271883 | IMPROVED ADOPTIVE CELL TRANSFER THERAPY FOR CANCER | SHUPE, ELIZABETH A | 70d |
| 18390880 | VARIANT-SPECIFIC EXOGENOUS DNA TEMPLATE-FREE CORRECTION OF PATHOGENIC VARIANTS | MEYERING, SHABANA SHABBEER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16630547 | DNA TARGETS AS TISSUE-SPECIFIC METHYLATION MARKERS | WOOLWINE, SAMUEL C | 29d |
| 18271883 | IMPROVED ADOPTIVE CELL TRANSFER THERAPY FOR CANCER | SHUPE, ELIZABETH A | 70d |
| 18866750 | GENETICALLY ENGINEERED MUCOSAL-ASSOCIATED INVARIANT T (MAIT) CELLS FOR ADOPTIVE TRANSFER CELLTHERAPY | MONTANARI, DAVID A | — |
| 18846130 | COMPOSITIONS FOR REMOVING MICROBIAL BIOFILM OR INHIBITING FORMATION THEREOF | KWON, JOHN SEUNGJAI | — |
| 18390880 | VARIANT-SPECIFIC EXOGENOUS DNA TEMPLATE-FREE CORRECTION OF PATHOGENIC VARIANTS | MEYERING, SHABANA SHABBEER | — |
| 17528699 | METHOD AND KIT FOR DETERMINING THE TISSUE OR CELL ORIGIN OF DNA | GOLDBERG, JEANINE ANNE | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| 4100 | 1 |
| 1643 | 1 |
| 1682 | 1 |
| 1681 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18866750 | GENETICALLY ENGINEERED MUCOSAL-ASSOCIATED INVARIANT T (MAIT) CELLS FOR ADOPTIVE TRANSFER CELLTHERAPY | MONTANARI, DAVID A | 1632 | §103 | Non-Final OA | — | Pending | Nov 18, 2024 |
| 18846130 | COMPOSITIONS FOR REMOVING MICROBIAL BIOFILM OR INHIBITING FORMATION THEREOF | KWON, JOHN SEUNGJAI | — | §103 | Non-Final OA | — | Pending | Sep 11, 2024 |
| 18390880 | VARIANT-SPECIFIC EXOGENOUS DNA TEMPLATE-FREE CORRECTION OF PATHOGENIC VARIANTS | MEYERING, SHABANA SHABBEER | 4100 | §102§103§112 | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18271883 | IMPROVED ADOPTIVE CELL TRANSFER THERAPY FOR CANCER | SHUPE, ELIZABETH A | 1643 | §102§103§112 | Non-Final OA | 70d | Pending | Jul 12, 2023 |
| 17528699 | METHOD AND KIT FOR DETERMINING THE TISSUE OR CELL ORIGIN OF DNA | GOLDBERG, JEANINE ANNE | 1682 | §112DP | Non-Final OA | — | Pending | Nov 17, 2021 |
| 16630547 | DNA TARGETS AS TISSUE-SPECIFIC METHYLATION MARKERS | WOOLWINE, SAMUEL C | 1681 | §101 | Final Rejection | 29d | Pending | Jan 13, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial